Leuprolide acetate 7.5mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal area ...
Leuprolide acetate 30mg; depot susp for IM inj; preservative-free. Store between 20° to 25°C (68° to 77°F); excursions permitted to 15°C to 30°C (59°F to86°F). Give as single IM inj into gluteal area, ...
ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...
ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...
Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results